Plasma‐based analysis of ERBB2 mutational status by multiplex digital PCR in a large series of patients with metastatic breast cancer
Molecular Oncology · 2024
DOI: 10.1002/1878-0261.13592 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2024. Verfasst von Julien Corné und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Centre Eugène Marquis, Unicancer, Rennes, France. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Breast Neoplasms, Mutation, Neoplasm Metastasis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Seagen.
Abstract (Originalsprache)
Erb‐b2 receptor tyrosine kinase 2 ( ERBB2 )‐activating mutations are therapeutically actionable alterations found in various cancers, including metastatic breast cancer (MBC). We developed multiplex digital PCR assays to detect and quantify ERBB2 mutations in circulating tumor DNA from liquid biopsies. We studied the plasma from 272 patients with hormone‐receptor‐positive, human epidermal growth factor receptor 2‐negative (HR+/HER2−) MBC to detect 17 ERBB2 mutations using a screening assay. The assay was developed on the three‐color Crystal dPCR™ naica® platform with a two‐step strategy for precise mutation identification. We found that nine patients (3.3%) harbored at least one ERBB2 mutation. The mutation rate was higher in patients with lobular histology (5.9%) compared to invasive breast carcinoma of no special type (2.6%). A total of 12 mutations were found with the following frequencies: L755S (25.00%), V777L (25.00%), S310Y (16.67%), L869R (16.67%), S310F (8.33%), and D769H (8.33%). Matched tumor samples from six patients identified the same mutations with an 83% concordance rate. In summary, our highly sensitive multiplex digital PCR assays are well suited for plasma‐based monitoring of ERBB2 mutational status in patients with MBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, Centre Eugène Marquis, Unicancer, Rennes, France.
- Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.
- INSERM U1242, University of Rennes, France.
ORCID-Profile: Julien Corné
Förderung
- Seagen
Zitieren
APA
Corné, J., Quillien, V., Godey, F., Cherel, M., Cochet, A., Le Du, F., Robert, L., Bourien, H., Brunot, A., Crouzet, L., Perrin, C., Lefeuvre-Plesse, C., Diéras, V., & De la Motte Rouge, T. (2024). Plasma‐based analysis of ERBB2 mutational status by multiplex digital PCR in a large series of patients with metastatic breast cancer. Molecular Oncology. https://doi.org/10.1002/1878-0261.13592
Vancouver
Corné J, Quillien V, Godey F, Cherel M, Cochet A, Le Du F, et al. Plasma‐based analysis of ERBB2 mutational status by multiplex digital PCR in a large series of patients with metastatic breast cancer. Molecular Oncology. 2024. doi:10.1002/1878-0261.13592
BibTeX
@article{Corn2024,
author = {Corné, Julien and Quillien, Véronique and Godey, Florence and Cherel, Mathilde and Cochet, Agathe and Le Du, Fanny and Robert, Lucie and Bourien, Héloïse and Brunot, Angélique and Crouzet, Laurence and Perrin, Christophe and Lefeuvre-Plesse, Claudia and Diéras, Véronique and De la Motte Rouge, Thibault},
title = {Plasma‐based analysis of ERBB2 mutational status by multiplex digital PCR in a large series of patients with metastatic breast cancer},
journal = {Molecular Oncology},
year = {2024},
doi = {10.1002/1878-0261.13592}
}
EUVIMED